Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases
Brain tumors are notoriously difficult to treat. The blood-brain barrier provides a sanctuary site where residual and metastatic cancer cells can evade most therapeutic modalities. The delicate nature of the brain further complicates the decision of eliminating as much tumorous tissue as possible wh...
Main Authors: | Janik Puttemans, Tony Lahoutte, Matthias D’Huyvetter, Nick Devoogdt |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-08-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/11/8/376 |
Similar Items
-
Preclinical Targeted α- and β<sup>−</sup>-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
by: Janik Puttemans, et al.
Published: (2020-04-01) -
Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview
by: Andrea Cimini, et al.
Published: (2021-08-01) -
Blood–Brain Barrier, Cell Junctions, and Tumor Microenvironment in Brain Metastases, the Biological Prospects and Dilemma in Therapies
by: Zhiyuan Guan, et al.
Published: (2021-08-01) -
Hypofractionated Radiation Therapy for Large Brain Metastases
by: Giuseppina Laura Masucci
Published: (2018-10-01) -
Sudden death associated with melanoma brain metastases
by: Durão H Carlos, et al.
Published: (2018-09-01)